Provided by Tiger Fintech (Singapore) Pte. Ltd.

Scilex Holding Company

6.09
+0.20003.40%
Volume:40.78K
Turnover:247.53K
Market Cap:42.34M
PE:-0.29
High:6.33
Open:5.81
Low:5.73
Close:5.89
Loading ...

Company Profile

Company Name:
Scilex Holding Company
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
111
Office Location:
960 San Antonio Road,Palo Alto,California,United States
Zip Code:
94303
Fax:
- -
Introduction:
Scilex Holding Company, a biopharmaceutical company, focuses on acquiring, developing, and commercializing non-opioid management products for the treatment of acute and chronic pain. It offers ZTlido, a prescription lidocaine topical product for the relief of neuropathic pain related with postherpetic neuralgia, which is a form of post-shingles nerve pain. The company also develops SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trial for the treatment of low back pain; and SP-104 (4.5 mg), a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.